selected variants of the H1650 and H1975 cell lines for resistance to osimertinib to create models in which mechanisms of resistance can be characterized and tested for potential methods to overcome that resistance. Method: Cells were exposed continuously to a single concentration of osimertinib, in some cases with the inclusion of verapamil to avoid possible selection of multidrug-resistant cells. After 4 weeks, with weekly changes of drug-medium, clonal cell lines were selected from H1650 cultured in the presence of 25 or 50 mM osimertinib plus 10 mM verapamil, and selected from H1975 cultured in 6 or 10 mM osimertinib alone or 5 mM osimertinib plus 10 mM verapamil. Result: The H1650 osimertinib-resistant cell lines (H1650/osi-25a/VPL and H1650/osi-50a/VPL) are 1.6-to 1.8-fold resistant to osimertinib. The H1975 osimertinib-resistant cell lines (H1975/osi-6b, osi-10c, and osi-5b/VPL) were, respectively, 90-, 95-, and 38-fold resistant to osimertinib. None of the cell lines was cross-resistant to imatinib. The compound 2-(benzylsulfonyl)-1-(1H-indol-3-yl)-1,2-dihydroisoquinoline (IBR2) is an inhibitor of the DNA repair protein RAD51 and enhances cytotoxicity of EGFR inhibitors against numerous cell lines (Ferguson et al., JPET 2018 , doi.org/10.1124 Background: Next-generation sequencing (NGS) of cell-free circulating tumor DNA (cfDNA) enables a non-invasive option for comprehensive genomic analysis of non-small cell lung cancer (NSCLC) patients. Although plasma-detected genomic alterations have been shown to predict targeted therapy response, evidence of durability of response is lacking or limited to small cohorts as is the impact of cfDNA NGS results on clinical decision making. Method: In this retrospective study, data was collected on stage IIIB/IV NSCLC patients between the years 2014-2017 in Israel. We utilized cfDNA NGS (Guardant360) which covers the seven genes targetable with FDA-approved therapies in NSCLC. Result: 116 consecutively NSCLC patients were tested, 41.4% (48/116) before 1 st line therapy (Group A), 34.5% (40/116) upon progression on chemotherapy or immunotherapy (Group B1) and 24.1% (28/116) upon progression on EGFR TKIs (Group B2). Targetable genomic alterations were found in 65% of group A (15/48), 53% in group B1 (21/ 40) and 71% in group B2 (20/28). Treatment decision was changed to targeted therapy based on cfDNA NGS analysis in 23% (11/48), 25% (10/40) and 32% (9/28), respectively (total cohort 26%; 30/116). Response assessment (RECIST) showed complete response in 4% (1/ 28), partial response in 39% (11/28), stable disease in 32% (9/28) and progressive disease in 25% (7/28). Total objective response rate (ORR) was 43% and disease control rate was 75% for 5 months treatment duration. Conclusion: Comprehensive cfDNA testing impacted clinical decisions in 23% of naïve patients, 25% in patients who progressed on chemotherapy and 32% in EGFR TKI progressors. Median treatment duration was 5 months. This retrospective study extends previous reports by showing that responses based on cfDNA are durable and change treatment decisions at initial presentation and at progression. Keywords: liquid biopsy, non-small cell lung cancer, next generation sequencing P3.01-29 St.Iv Lung Adenocarcinoma Treated by First-Line EGFReTyrosine Kinase Inhibitors-Survival, EGFR Mutation, Histologic Subtype T. Gil, 1 G. Czy_ zewicz, 1 M. Skoczek, 1 P. Wójcik, 2 P. Hajder, 3 B. Kołodziejczyk, 1 W. Cie slak, 1 J. Ku_ zd_ zał 1 1 Department of Thoracic Surgery, Jagiellonian University, John Paul Ii Hospital, Cracow/PL, 2 Jagiellonian University, John Paul Ii Hospital, Cracow/PL, 3 Agh Ust, Department of Applied Computer Science and Modelling, Cracow/PL Background: The aim of the study is to evaluate the correlation of survival, EGFR mutation and histologic subtype of stage IV lung sensitive mutant adenocarcinoma treated with first-line EGFRetyrosine kinase inhibitors (EGFR-TKI). o:p> Method: We retrospectively analyzed the clinical outcomes of 60 consecutive patients with EGFR-TKI sensitive mutations (exon 19 deletion or exon 21 L858R ) who received first-line erlotinib, gefitinib or afatinib therapy between October 2011 and September 2017. Histologic subtype was classified according to the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society pulmonary adenocarcinoma classification. Result: There were 60 patient enrolled, including 26 men, mean age 68.88 years (range: 49-89 ) and 34 women, mean age 65.68 years (range: 44-82). The average survival in women was 14.1 months and in men it was 13.3 months. Average survival in 28 patients were treated with Erlotinib was 14.51 months, in 18 patients treated with Gefitinib it was 12.79 months and in 14 patients treated with Afatinib it was 13.55 months. In 30 patients with the mutations (exon 19 deletion), the mean survival was 14.56 months. In the group of 26 patients with mutations (exon 21 L858R ), the mean survival was 12.68 months. The mean survival in the group of patients with acinar adenocarcinoma was 15.49 months, and in solid adenocarcinoma -4.8 months. Currently, 21 patients are alive and remain in observation, 12 of them are treated and 39 patients died. In the multidimensional linear regression analysis, smoking was a factor decreasing the survival at p ¼ 0.12, male gender decreased the survival rate p ¼ 0.04, and the type of cancer subtype increased the survival rate p ¼ 0.04. Erlotinib influenced the increase in survival at p ¼ 0.15 Conclusion: Mutation in (exon 19 deletion), histological subtype of tumor and Erlotinib treatment are factors significantly affecting the survival of patients with stage IV adenocarcinoma of the lung.The EGFR mutation frequency is higher in the acinar subtype than in other subtypes. Keywords: Lung adenocarcinoma, EGFR mutation, EGFR-tyrosine kinase inhibitors, IASLC/ATS/ERS classification P3.01-30 Treatment Sequencing in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC) in Japan
